Need help finding what you are looking for?
Contact Us
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2028272
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2028272
CAR-T Cell Therapy Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
PUBLISHED:
PAGES: 149 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
Growth Factors of CAR-T cell therapy Market
The global CAR-T cell therapy market is experiencing strong expansion due to rising cancer prevalence, rapid advancements in immunotherapy, and increasing investment in personalized medicine. CAR-T (Chimeric Antigen Receptor T-cell) therapy is a revolutionary form of cancer treatment that modifies a patient's T-cells to recognize and destroy cancer cells, offering targeted and durable responses in hematologic malignancies.
Market Size and Forecast
According to the industry data:
- 2025 Market Size: USD 8.95 billion
- 2026 Market Size: USD 10.92 billion
- 2034 Market Forecast: USD 19.25 billion
- CAGR (2026-2034): 7.34%
The market is expected to nearly double between 2025 and 2034, reflecting strong long-term adoption of CAR-T therapies in oncology treatment pathways.
Regional Market Overview
North America (Market Leader)
- 2025 Value: USD 6.3 billion
- 2026 Value: USD 7.73 billion
- Share in 2025: 70.41% of global market
North America dominates the CAR-T cell therapy market due to advanced healthcare infrastructure, strong reimbursement systems, high cancer incidence, and early adoption of innovative therapies. The United States remains the key revenue generator in this region.
Europe
- 2025 Value: USD 1.67 billion
- 2026 Value: USD 2.01 billion
- Share in 2025: 18.67%
Europe shows steady growth supported by government funding, clinical research programs, and increasing regulatory approvals for CAR-T products.
Asia Pacific (Fastest Growing Region)
- 2025 Value: USD 0.80 billion
- 2026 Value: USD 0.99 billion
- Share in 2025: 8.94%
Asia Pacific is expected to record the highest growth rate due to rising cancer cases, expanding clinical trials, and increasing healthcare investments in countries like China, Japan, and India.
Rest of the World
- 2025 Value: USD 0.17 billion
- 2026 Value: USD 0.20 billion
- Share in 2025: 1.97%
Growth in this region is supported by improving healthcare infrastructure and gradual expansion of oncology treatment access.
Market Drivers
The CAR-T cell therapy market is driven by several key factors:
- Rising global incidence of hematologic cancers such as leukemia, lymphoma, and multiple myeloma
- Increasing approvals of CAR-T therapies by regulatory bodies like the FDA and EMA
- Expansion of clinical trials, with over 440 pipeline candidates in 2023
- Advancements in gene editing technologies such as CRISPR
- Growth in patient assistance programs and healthcare awareness initiatives
- Increasing collaborations between biotech and pharmaceutical companies
Market Trends
Major trends shaping the industry include:
- Shift toward allogeneic (off-the-shelf) CAR-T therapies, improving scalability and reducing treatment time
- Expansion of R&D partnerships (e.g., BioNTech-Autolus collaborations)
- Rapid growth in clinical pipeline and experimental CAR-T therapies
- Increasing focus on treating multiple indications beyond blood cancers
Market Restraints
Despite strong growth, the market faces challenges:
- High treatment cost ranging from USD 373,000 to over USD 1 million per patient
- Limited patient eligibility due to strict treatment conditions
- Complex manufacturing and personalized production processes
- Lack of reimbursement support in emerging economies
These factors restrict widespread adoption, particularly in low- and middle-income countries.
Segmentation Overview
- By Drug Type: Axicabtagene ciloleucel (Yescarta) leads the market
- By Indication: Non-Hodgkin lymphoma dominates with over 65% share
- By End User: Hospitals hold the largest share due to complex treatment requirements
Competitive Landscape
Key players include:
- Gilead Sciences, Inc.
- Novartis AG
- Bristol-Myers Squibb Company
- Johnson & Johnson (Janssen)
- Caribou Biosciences, Inc.
- JW Therapeutics
- CARsgen Therapeutics
Gilead Sciences leads the market primarily through strong sales of Yescarta, while Bristol-Myers Squibb continues expanding its CAR-T pipeline globally.
Conclusion
The global CAR-T cell therapy market is on a strong growth trajectory, projected to increase from USD 8.95 billion in 2025 to USD 10.92 billion in 2026, and further reach USD 19.25 billion by 2034. Driven by rising cancer burden, technological advancements, and expanding clinical applications, CAR-T therapy is expected to become a cornerstone of next-generation oncology treatment despite challenges related to cost and accessibility.
Segmentation By Drug Type
- Axicabtagene Ciloleucel (Yescarta)
- Brexucabtagene Autoleucel (Tecartus)
- Ciltacabtagene Autoleucel (Carvykti)
- Idecabtagene Vicleucel (Abecma)
- Lisocabtagene Maraleucel (Breyanzi)
- Tisagenlecleucel (Kymriah)
- Others
By Indication
- Acute Lymphoblastic Leukemia
- Non-Hodgkin Lymphoma
- Multiple Myeloma
By End-user
- Hospitals
- Oncology Treatment Centers
By Region
- North America (By Drug Type, By Indication, By End-user, By Country)
- U.S.
- Canada
- Europe (By Drug Type, By Indication, By End-user, By Country/Sub-region)
- Germany
- U.K.
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
- Asia Pacific (By Drug Type, By Indication, By End-user, By Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Rest of the World (By Drug Type, By Indication, By End-user)
Product Code: FBI108455
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Chronic Diseases, by Key Countries/Regions, 2025/2025
- 4.2. Pipeline Analysis, By Key Players
- 4.3. Technological Advancements
- 4.4. New Product Launches, By Key Players
- 4.5. Key Industry Developments: Mergers, Acquisitions & Partnerships
- 4.6. Impact of COVID-19 on the Market
5. Global CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Drug Type
- 5.1.1. Axicabtagene Ciloleucel (Yescarta)
- 5.1.2. Brexucabtagene Autoleucel (Tecartus)
- 5.1.3. Ciltacabtagene Autoleucel (Carvykti)
- 5.1.4. Idecabtagene Vicleucel (Abecma)
- 5.1.5. Lisocabtagene Maraleucel (Breyanzi)
- 5.1.6. Tisagenlecleucel (Kymriah)
- 5.1.7. Others
- 5.2. Market Analysis, Insights and Forecast - By Indication
- 5.2.1. Acute lymphoblastic leukemia
- 5.2.2. Non-Hodgkin lymphoma
- 5.2.3. Multiple Myeloma
- 5.3. Market Analysis, Insights and Forecast - By End User
- 5.3.1. Hospitals
- 5.3.2. Oncology Treatment Centers
- 5.4. Market Analysis, Insights and Forecast - By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Rest of the World
6. North America CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Drug Type
- 6.1.1. Axicabtagene Ciloleucel (Yescarta)
- 6.1.2. Brexucabtagene Autoleucel (Tecartus)
- 6.1.3. Ciltacabtagene Autoleucel (Carvykti)
- 6.1.4. Idecabtagene Vicleucel (Abecma)
- 6.1.5. Lisocabtagene Maraleucel (Breyanzi)
- 6.1.6. Tisagenlecleucel (Kymriah)
- 6.1.7. Others
- 6.2. Market Analysis, Insights and Forecast - By Indication
- 6.2.1. Acute lymphoblastic leukemia
- 6.2.2. Non-Hodgkin lymphoma
- 6.2.3. Multiple Myeloma
- 6.3. Market Analysis, Insights and Forecast - By End User
- 6.3.1. Hospitals
- 6.3.2. Oncology Treatment Centers
- 6.4. Market Analysis, Insights and Forecast - By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Drug Type
- 7.1.1. Axicabtagene Ciloleucel (Yescarta)
- 7.1.2. Brexucabtagene Autoleucel (Tecartus)
- 7.1.3. Ciltacabtagene Autoleucel (Carvykti)
- 7.1.4. Idecabtagene Vicleucel (Abecma)
- 7.1.5. Lisocabtagene Maraleucel (Breyanzi)
- 7.1.6. Tisagenlecleucel (Kymriah)
- 7.1.7. Others
- 7.2. Market Analysis, Insights and Forecast - By Indication
- 7.2.1. Acute lymphoblastic leukemia
- 7.2.2. Non-Hodgkin lymphoma
- 7.2.3. Multiple Myeloma
- 7.3. Market Analysis, Insights and Forecast - By End User
- 7.3.1. Hospitals
- 7.3.2. Oncology Treatment Centers
- 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.4.1. U.K.
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Scandinavia
- 7.4.7. Rest of Europe
8. Asia Pacific CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Drug Type
- 8.1.1. Axicabtagene Ciloleucel (Yescarta)
- 8.1.2. Brexucabtagene Autoleucel (Tecartus)
- 8.1.3. Ciltacabtagene Autoleucel (Carvykti)
- 8.1.4. Idecabtagene Vicleucel (Abecma)
- 8.1.5. Lisocabtagene Maraleucel (Breyanzi)
- 8.1.6. Tisagenlecleucel (Kymriah)
- 8.1.7. Others
- 8.2. Market Analysis, Insights and Forecast - By Indication
- 8.2.1. Acute lymphoblastic leukemia
- 8.2.2. Non-Hodgkin lymphoma
- 8.2.3. Multiple Myeloma
- 8.3. Market Analysis, Insights and Forecast - By End User
- 8.3.1. Hospitals
- 8.3.2. Oncology Treatment Centers
- 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.4.1. China
- 8.4.2. Japan
- 8.4.3. India
- 8.4.4. Australia
- 8.4.5. Southeast Asia
- 8.4.6. Rest of Asia Pacific
9. Rest of the World CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Drug Type
- 9.1.1. Axicabtagene Ciloleucel (Yescarta)
- 9.1.2. Brexucabtagene Autoleucel (Tecartus)
- 9.1.3. Ciltacabtagene Autoleucel (Carvykti)
- 9.1.4. Idecabtagene Vicleucel (Abecma)
- 9.1.5. Lisocabtagene Maraleucel (Breyanzi)
- 9.1.6. Tisagenlecleucel (Kymriah)
- 9.1.7. Others
- 9.2. Market Analysis, Insights and Forecast - By Indication
- 9.2.1. Acute lymphoblastic leukemia
- 9.2.2. Non-Hodgkin lymphoma
- 9.2.3. Multiple Myeloma
- 9.3. Market Analysis, Insights and Forecast - By End User
- 9.3.1. Hospitals
- 9.3.2. Oncology Treatment Centers
10. Competitive Analysis
- 10.1. Global Market Share Analysis (2025)
- 10.2. Company Profiles
- 10.2.1. Gilead Sciences, Inc.
- 10.2.1.1. Overview
- 10.2.1.2. Products & Services
- 10.2.1.3. SWOT Analysis
- 10.2.1.4. Recent Developments
- 10.2.1.5. Strategies
- 10.2.1.6. Financials (Based on Availability)
- 10.2.2. Novartis AG
- 10.2.2.1. Overview
- 10.2.2.2. Products & Services
- 10.2.2.3. SWOT Analysis
- 10.2.2.4. Recent Developments
- 10.2.2.5. Strategies
- 10.2.2.6. Financials (Based on Availability)
- 10.2.3. Bristol-Myers Squibb Company
- 10.2.3.1. Overview
- 10.2.3.2. Products & Services
- 10.2.3.3. SWOT Analysis
- 10.2.3.4. Recent Developments
- 10.2.3.5. Strategies
- 10.2.3.6. Financials (Based on Availability)
- 10.2.4. Johnson & Johnson Services, Inc. (Janssen Global Services, LLC)
- 10.2.4.1. Overview
- 10.2.4.2. Products & Services
- 10.2.4.3. SWOT Analysis
- 10.2.4.4. Recent Developments
- 10.2.4.5. Strategies
- 10.2.4.6. Financials (Based on Availability)
- 10.2.5. Caribou Biosciences, Inc.
- 10.2.5.1. Overview
- 10.2.5.2. Products & Services
- 10.2.5.3. SWOT Analysis
- 10.2.5.4. Recent Developments
- 10.2.5.5. Strategies
- 10.2.5.6. Financials (Based on Availability)
- 10.2.6. CARsgenTherapeutics Co., Ltd
- 10.2.6.1. Overview
- 10.2.6.2. Products & Services
- 10.2.6.3. SWOT Analysis
- 10.2.6.4. Recent Developments
- 10.2.6.5. Strategies
- 10.2.6.6. Financials (Based on Availability)
- 10.2.7. JW Therapeutics (Shanghai) Co., Ltd.
- 10.2.7.1. Overview
- 10.2.7.2. Products & Services
- 10.2.7.3. SWOT Analysis
- 10.2.7.4. Recent Developments
- 10.2.7.5. Strategies
- 10.2.7.6. Financials (Based on Availability)
- 10.2.8. Cartesian Therapeutics, Inc.
- 10.2.8.1. Overview
- 10.2.8.2. Products & Services
- 10.2.8.3. SWOT Analysis
- 10.2.8.4. Recent Developments
- 10.2.8.5. Strategies
- 10.2.8.6. Financials (Based on Availability)
- 10.2.9. Aurora Biopharma
- 10.2.9.1. Overview
- 10.2.9.2. Products & Services
- 10.2.9.3. SWOT Analysis
- 10.2.9.4. Recent Developments
- 10.2.9.5. Strategies
- 10.2.9.6. Financials (Based on Availability)
- 10.2.1. Gilead Sciences, Inc.
Product Code: FBI108455
List of Tables
- Table 1: Global CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
- Table 2: Global CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Indication, 2021-2034
- Table 3: Global CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By End User, 2021-2034
- Table 4: Global CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Region, 2021-2034
- Table 5: North America CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
- Table 6: North America CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Indication, 2021-2034
- Table 7: North America CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By End User, 2021-2034
- Table 8: North America CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 9: Europe CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
- Table 10: Europe CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Indication, 2021-2034
- Table 11: Europe CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By End User, 2021-2034
- Table 12: Europe CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
- Table 13: Asia Pacific CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
- Table 14: Asia Pacific CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Indication, 2021-2034
- Table 15: Asia Pacific CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By End User, 2021-2034
- Table 16: Asia Pacific CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
- Table 17: Rest of the World CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
- Table 18: Rest of the World CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By Indication, 2021-2034
- Table 19: Rest of the World CAR-T Cell Therapy Market Revenue (USD billion) Forecast, By End User, 2021-2034
List of Figures
- Figure 1: Global CAR-T Cell Therapy Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global CAR-T Cell Therapy Market Value Share (%), By Drug Type, 2025 & 2034
- Figure 3: Global CAR-T Cell Therapy Market Value Share (%), By Indication, 2025 & 2034
- Figure 4: Global CAR-T Cell Therapy Market Value Share (%), By End User, 2025 & 2034
- Figure 5: Global CAR-T Cell Therapy Market Value Share (%), By Region, 2025 & 2034
- Figure 6: North America CAR-T Cell Therapy Market Value (USD billion), By Drug Type, 2025 & 2034
- Figure 7: North America CAR-T Cell Therapy Market Value Share (%), By Drug Type, 2025
- Figure 8: North America CAR-T Cell Therapy Market Value (USD billion), By Indication, 2025 & 2034
- Figure 9: North America CAR-T Cell Therapy Market Value Share (%), By Indication, 2025
- Figure 10: North America CAR-T Cell Therapy Market Value (USD billion), By End User, 2025 & 2034
- Figure 11: North America CAR-T Cell Therapy Market Value Share (%), By End User, 2025
- Figure 12: North America CAR-T Cell Therapy Market Value (USD billion), by Country, 2025 & 2034
- Figure 13: North America CAR-T Cell Therapy Market Value Share (%), by Country, 2025
- Figure 14: Europe CAR-T Cell Therapy Market Value (USD billion), By Drug Type, 2025 & 2034
- Figure 15: Europe CAR-T Cell Therapy Market Value Share (%), By Drug Type, 2025
- Figure 16: Europe CAR-T Cell Therapy Market Value (USD billion), By Indication, 2025 & 2034
- Figure 17: Europe CAR-T Cell Therapy Market Value Share (%), By Indication, 2025
- Figure 18: Europe CAR-T Cell Therapy Market Value (USD billion), By End User, 2025 & 2034
- Figure 19: Europe CAR-T Cell Therapy Market Value Share (%), By End User, 2025
- Figure 20: Europe CAR-T Cell Therapy Market Value (USD billion), by Country/ Sub-Region, 2025 & 2034
- Figure 21: Europe CAR-T Cell Therapy Market Value Share (%), by Country/ Sub-Region, 2025
- Figure 22: Asia Pacific CAR-T Cell Therapy Market Value (USD billion), By Drug Type, 2025 & 2034
- Figure 23: Asia Pacific CAR-T Cell Therapy Market Value Share (%), By Drug Type, 2025
- Figure 24: Asia Pacific CAR-T Cell Therapy Market Value (USD billion), By Indication, 2025 & 2034
- Figure 25: Asia Pacific CAR-T Cell Therapy Market Value Share (%), By Indication, 2025
- Figure 26: Asia Pacific CAR-T Cell Therapy Market Value (USD billion), By End User, 2025 & 2034
- Figure 27: Asia Pacific CAR-T Cell Therapy Market Value Share (%), By End User, 2025
- Figure 28: Asia Pacific CAR-T Cell Therapy Market Value (USD billion), by Country/ Sub-Region, 2025 & 2034
- Figure 29: Asia Pacific CAR-T Cell Therapy Market Value Share (%), by Country/ Sub-Region, 2025
- Figure 30: Rest of the World CAR-T Cell Therapy Market Value (USD billion), By Drug Type, 2025 & 2034
- Figure 31: Rest of the World CAR-T Cell Therapy Market Value Share (%), By Drug Type, 2025
- Figure 32: Rest of the World CAR-T Cell Therapy Market Value (USD billion), By Indication, 2025 & 2034
- Figure 33: Rest of the World CAR-T Cell Therapy Market Value Share (%), By Indication, 2025
- Figure 34: Rest of the World CAR-T Cell Therapy Market Value (USD billion), By End User, 2025 & 2034
- Figure 35: Rest of the World CAR-T Cell Therapy Market Value Share (%), By End User, 2025
- Figure 36: Global CAR-T Cell Therapy Market Share (%), By Company, 2025
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.